1. At a Glance
Anupam Rasayan India Ltd ( NSE: ANURAS ) just pulled off a quarter that felt like it was sponsored by caffeine and contracts.
Q2 FY26 revenue came in at ₹ 739 Cr (+149 % YoY!) and PAT ₹ 57 Cr (+166 % YoY!) — basically the chemical version of a Red Bull ad.
At ₹ 1,065 a share and a market cap ₹ 12,121 Cr, the stock trades at 80 × earnings, because apparently optimism is a solvent now.
ROE 3.3 %, ROCE 7.3 %, Debt ₹ 1,223 Cr (D/E 0.38 ×), Book Value ₹ 281, and Dividend Yield 0.07 %.
Promoter holding 59.1 % ( down 2 pp QoQ ) — someone clearly sold a few molecules for cash.
Operating margin 25 %. Order book ₹ 8,900 Cr.
Six plants in Gujarat churning out 27,000 MT of chemicals and one very ambitious storyline.
2. Introduction
When chemistry students dream big, they usually land in a lab. Anupam Rasayan landed on Dalal Street.
Founded in 1984, the company specializes in life-science and other specialty chemicals — serving everything from crop protection to lip protection.
Its clients read like a science Olympiad sponsor list — Syngenta, Adama, Sumitomo, DuPont, and Nissei. Top 10 clients = 77 % of revenues, which is comforting until one client sneezes.
The company’s order book is bigger than its balance sheet ( ₹ 8,900 Cr vs ₹ 5,650 Cr assets ). That’s ambition, not arithmetic.
They’ve signed LOIs worth hundreds of millions with Japanese and Korean firms for battery solvents and fluorine chemicals — because every Indian manufacturer now wants to be part of the EV fairy tale.
But beneath the glow of solar plants and press releases, ROE is barely 3 %. The balance sheet glows brighter than the profit sheet.
3. Business Model – WTF Do They Even Do?
In one line: They mix expensive molecules for other people’s patents and make it sound like alchemy.
Life Science Specialty Chemicals
